Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
1167 articles by Jacob Bell
-
Sarepta wins FDA approval of another drug for rare muscular dystrophy
Feb. 25, 2021 -
Merck to buy autoimmune drugmaker for $2B
Feb. 25, 2021 -
After FDA feedback, a biotech's ALS therapy faces murky path forward
Feb. 22, 2021 -
Lilly wagers almost $1B on Rigel's drugs for immune and nervous systems
Feb. 18, 2021 -
Gates Foundation backs Novartis' search for a sickle cell cure
Feb. 17, 2021 -
AbbVie exploring how CRISPR gene editing can improve cell therapies
Feb. 10, 2021 -
Lilly CFO steps down after investigation found 'inappropriate' behavior
Feb. 9, 2021 -
Biogen laser-focused on Alzheimer's drug as rest of business falters
Feb. 3, 2021 -
Vertex comes to a crossroads
Feb. 2, 2021 -
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca
Feb. 1, 2021 -
FDA delays verdict for Biogen's closely watched Alzheimer's drug, raising investor optimism
Jan. 29, 2021 -
Safety finding weighs on Pfizer's inflammation drug, and could spell trouble for others
Jan. 27, 2021 -
FDA approves first-of-its-kind lupus drug
Jan. 25, 2021 -
Long-acting HIV drug secures FDA approval, giving GSK a competitive boost
Jan. 22, 2021 -
Biohaven adds to a long list of Alzheimer's drug failures
Jan. 19, 2021 -
Dana-Farber launches venture fund targeting incurable cancers
Jan. 15, 2021 -
5 trends in biotech dealmaking to watch in 2021
Jan. 13, 2021 -
Lilly rockets up on mixed Alzheimer's results
Jan. 11, 2021 -
Alnylam, with positive data in hand, prepares to submit 4th drug for approval
Jan. 7, 2021 -
Dewpoint forges another big pharma partnership — and a potential rivalry
Jan. 6, 2021 -
A new, well-connected biotech aims to fight cancer with viruses
Jan. 5, 2021 -
Amgen's asthma drug takes a hit, making for stiffer competition with Regeneron
Dec. 22, 2020 -
Cancer case puts UniQure's hemophilia gene therapy on hold, raising alarms
Dec. 21, 2020 -
Novartis acquires a small biotech and its trio of brain drugs
Dec. 17, 2020 -
Gilead hands back some rights to key drug from Galapagos deal
Dec. 16, 2020